Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

476
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
476
Liver Histology01:27

Liver Histology

607
The microscopic anatomy of the liver is a complex and intricate system that comprises numerous structural units known as liver lobules, each of which is comparable in size to a sesame seed. These hexagonal structures consist of plates of liver cells or hepatocytes, which are characterized by their versatility and abundance of cellular apparatus like rough and smooth ER, Golgi apparatus, peroxisomes, and mitochondria.
Hepatocytes perform a variety of essential functions. They secrete...
607
Liver Physiology01:30

Liver Physiology

442
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of  70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
442
Liver Regeneration01:24

Liver Regeneration

3.2K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
3.2K
Ultrasound II: Endoscopic Ultrasound and FibroScan01:25

Ultrasound II: Endoscopic Ultrasound and FibroScan

80
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
80

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Alcohol-Related Liver Disease: A Review.

JAMA·2026
Same author

Delisting From Clinical Improvement in Liver Cirrhosis: A Machine Learning Decision Tree Analysis.

Transplantation·2026
Same author

Validated Early Detection Metrics Reduce the Population Requiring Liver Fibrosis Screening.

Gastroenterology·2026
Same author

Hepatic Venous Pressure Gradient, Noninvasive Tests, and Prognosis Across the Subtypes of Advanced Steatotic Liver Disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver disease.

The Lancet regional health. Europe·2026
Same author

Implementation of evidence-based alcohol policies to reduce alcohol-related harm and liver disease to advance public health in Europe.

The Lancet regional health. Europe·2026

関連する実験動画

Updated: Jun 8, 2025

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

788

ステアトーシス肝疾患

Mads Israelsen1, Sven Francque2, Emmanuel A Tsochatzis3

  • 1Centre for Liver Research and Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark; Institute of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark.

Lancet (London, England)
|November 2, 2024
PubMed
まとめ
この要約は機械生成です。

代謝機能障害に関連したステアトス性肝疾患 (MASLD) とアルコール関連性肝疾患 (ALD) を含むステアトス性肝疾患は,肝硬変の主要な原因です. 早期に 線維症を検知し 新しい治療法で 死亡率を減らすことができます

さらに関連する動画

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
07:12

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

6.3K
Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells
09:15

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Published on: July 18, 2019

8.8K

関連する実験動画

Last Updated: Jun 8, 2025

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

788
Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
07:12

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

6.3K
Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells
09:15

Inducing and Characterizing Vesicular Steatosis in Differentiated HepaRG Cells

Published on: July 18, 2019

8.8K

科学分野:

  • 肝臓病と胃腸病
  • 代謝障害
  • 公衆衛生

背景:

  • ステアトス性肝疾患 (SLD) は,代謝機能障害に関連したステアトス性肝疾患 (MASLD) とアルコール関連性肝疾患 (ALD) を含む,異常な肝脂肪の蓄積によって特徴付けられます.
  • SLDは,EUと米国で肝硬変の主要な原因で,世界的に30%に影響を及ぼし,肥満,2型糖尿病とアルコールによって引き起こされています.
  • 炎症による肝繊維症の進行は,SLDにおける肝関連の死亡の主な予測因子です.

研究 の 目的:

  • ステアトス性肝疾患の最近の再分類と臨床実務と予後への影響について検討する.
  • 肝臓繊維症の早期発見のための共同診断枠組みを提案する.
  • MASLDの現在の管理戦略,治療目標,薬の開発について議論する.

主な方法:

  • SLDの分類,診断,治療における最近の進歩の文献レビューと合成.
  • SLDと肝硬変の流行と影響に関する疫学データの分析
  • 線維症の検出とMASLDの治療パイプラインの新興バイオマーカーのレビュー.

主要な成果:

  • SLDの再分類により,より統合された臨床的および予後的枠組みが提供されます.
  • 線維症のバイオマーカーと治療法の進歩は,SLDに関連する罹病率と死亡率を減らす可能性を秘めています.
  • 肝繊維症の早期発見を改善するために,共同診断アプローチが提案されています.

結論:

  • ステアトス性肝疾患の最新分類は 総合的なアプローチが必要です
  • 共同研究による肝繊維症の早期発見は 患者の治療の改善に不可欠です
  • 現在進行中の研究と薬の開発は,MASLDの治療と,SLDに関連する肝硬変の負担を減らすために有望です.